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g.2012.1Abstract Nek2A is an essential component of cell cycle progression. It regulates the reorganization
of the microtubule network at the G2/M transition and controls the centriole–centriole linkage of
the cells entering mitosis. The overexpression of Nek2A coding gene has been widely reported in
several cancer-associated disorders. In order to design a potent inhibitor and to control its expres-
sion mechanism, it is important to understand the structural orientation and the underlying molec-
ular mechanisms associated with its activity regulation. In this study we have summarized the
important information that will help in understanding the functional and activity regulation of
Nek2A splice variants, which will further facilitate in designing a potent inhibitor against the cancer
associated cases. We have also presented previously reported studies on the domain speciﬁcations
and inhibitor biosynthesis that provide an insight into its speciﬁc target residue regions for devel-
oping active and more potent inhibitors.
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Centrosome is an essential component of the cell cycle regu-
lation mechanism. Alteration in its function primarily leads
to several cell cycle disorders, including aneuploidy, which
is considered as the hallmark of cancer. Centrosomes are
composed of pairs of centrioles and the pericentriolar matrix
that determines the geometry of microtubule arrays through-
out the cell cycle, and thus inﬂuences the cell shape, polarity,
motility, spindle formation, chromosome segregation and reg-
ulates the overall cell cycle progression mechanism [1]. The
centrioles are considered among the most essential elements
of cilia and microtubule organization in the cell [1]. These
in turn play important roles in locomotion, transport and sig-
nalling. Aberrations in centriole/basal body formation and
function are associated with a plethora of human diseases,
including ciliopathies, brain diseases and cancer [2]. The
growing line evidence has further suggested the direct
involvement of centriole associated proteins in several cell cy-
cle aberrations and the associated disorders [3–5]. The bio-
genesis of centrioles is strictly controlled by a set of
proteins, the foremost including the rootelin, SAS-6, Plk1,
CEP68, CEP135, CEP164, CEP215, Mst1/Mst2, hSav1, C-
Nap1 and several other associated kinases such as Nek2
and Aurora-A [1,2,7]. Abnormal chromosome content, in
other words aneuploidy, is a hallmark of human cancers
which is largely affected by centrosomal dysfunction.
Kinases are vital for the execution and regulation of cell cy-
cle progression events. It is interesting that a single cell cycle
associated kinase is often involved in multiple cellular processes
during mitosis [8]. These mitotic kinases are usually located at
their speciﬁc sites within the cell and undertake their designated
roles. Nek2 is a cell cycle regulated kinase belonging to never in
mitosis A (NIMA) family and is highly enriched at the centro-
some, preferentially located at the proximal ends of the centri-
oles [9,10]. It was initially described as a mammalian structural
homologue of Aspergillus NIMA whose function was found to
be linked with chromosome condensation in mitosis [11,12].
Nek2 was found to be localized on the mid body of the telo-
phase cells [13]. Dynamic changes in subcellular localization
of Nek2 have been observed during the mitotic stages [13,14].
There is strong evidence that in mitotic cells Nek2 contributes
to centrosome separation and perhaps in reorganization of
the microtubule network at the G2/M transition [9,14]. Fur-
ther, it controls the centriole–centriole linkage of the cells enter-
ing mitosis by phosphorylating C-Nap1 [15]. Association of
Nek2 with chromosomes is shown to be evident once the cell
enters mitosis and maintains until the end of metaphase [12].
In line with functions in mitotic entry, Nek2 is a cell cycle-reg-
ulated kinase with activity low in G1, increased in S and G2,
and diminished after mitotic onset [1]. It has different splice
variants that show a diverse pattern of expression and activity
regulations and has been discussed below.2. Nek2 splice variants
Two well known C-terminal splicing variants of Nek2, namely
Nek2A and Nek2B, were identiﬁed in Xenopus embryos
[16,17] and in cultured human cells [18]. The combined abun-
dance and activity of the two forms peak in S and G2 phases of
the cell cycle, whereas Nek2A is speciﬁcally targeted for prote-
osomal destruction in mitosis [18]. The Nek2B splice variant
lacks a destruction box, thus it is resistant to mitotic destruc-
tion mediated by the anaphase-promoting complex and with-
stands destruction until the early G1 phase [18,19]. It was
shown to be present exclusively in the early Xenopus embryos
whereas the Nek2A splice variant appeared only after the neu-
rula stage [16]. It was recently suggested that Nek2B plays an
active role in promoting the assembly of the functional zygotic
centrosome in fertilized Xenopus eggs [20]. Nek2A and Nek2B
were shown to be expressed throughout early embryogenesis
but Nek2A showed a distinct feature by not being destroyed
after the cell has entered the mitotic stage [21]. Recently, a
third splice variant, Nek2C, was identiﬁed that lacks an
eight-amino acid internal sequence within the C-terminal do-
main of Nek2A [22]. Nek2C shares many properties with
Nek2A including kinase activity, dimerization, protein phos-
phatase 1 interaction, mitotic degradation, microtubule bind-
ing, and centrosome localization [22]. The biochemical and
physiological properties of the Nek2C splice variant are the
subject of further investigation. The variation in activity regu-
lation within these splice variants is the central point of re-
search. Fletcher et al. has shown that the depletion of
Nek2A and Nek2B has different effects on the mitotic delay
[23]. Upon examination, 84% of the control and 63% of the
Nek2A depleted cells showed mitotic exit in less than 2 h,
whereas only 30% of Nek2B depleted cells showed mitotic exit
during this time. Upon exiting mitosis 15–20% of the Nek2B
depleted cells was unable to complete cytokinesis resulting in
the formation of multinucleated cells [23]. They observed that
the mitotic delay and defects in exiting mitosis were not shown
after the downregulation of Nek2A alone. Authors further
demonstrated that the Nek2A and Nek2B have distinct roles
in regulating cell cycle progression and Nek2A but not Nek2B
is involved in the regulation of centrosome splitting prior to
mitotic entry. These observations clearly suggest the role of
C terminal region in determining the diverse range of functions
shown by these two splice variants. According to the authors
observation, down-regulation of Nek2B alone actually resulted
in a mitotic delay that can lead to mitotic defects, whereas the
same phenomena were not observed at a signiﬁcant level in the
Nek2A case [23]. Furthermore, the explanation of activity reg-
ulation for Nek2C has not yet been proposed. Individual as
well as the group examination of these splice variants, will pro-
vide a detailed insight into how they coordinate the cell cycle
progression and will help in elucidating their inter-regulatory
mechanisms.
Figure 1 Figure shows the Nek2A mediated regulation of centrosome disjunction pathway.
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Nek2A governs a wide range of activities that determine the
fate of cell cycle progression ranging from centrosome disjunc-
tion to spindle checkpoint signal regulation. The overall regu-
lation of Nek2A-mediated centrosome disjunction mechanism
is shown in Fig 1. Hec1, a kinetochore protein, is essentially
required for maintaining the proper spindle checkpoint cas-
cades and its depletion leads to the impairment of chromosome
congression and causes persistent activation of the spindle
checkpoint [24]. Hec1 is shown to be an active substrate of
Nek2, suggesting the possible involvement of Nek2 in the reg-
ulation of spindle checkpoint mechanism [25]. Recently, it was
also reported that Nek2A interacts physically with Mad1 and
is required for proper response to spindle damage [8]. The
hSav1, Mst1/Mst2 and Nek2 shares a common interaction mo-
tif known as the SARAH domain. The SARAH domain of
Nek2A is shown to interact with the components of the Hippo
pathway, which aids in proper centrosome disjunction [6]. In
60% of hSav1 or Mst1/Mst2-depleted cells, Nek2 was no long-
er detected at centrosomes, whereas the other cells also showed
notable loss in Nek2 signals [6]. Moreover, the Eg5-dependent
microtubule-pushing forces cooperated jointly with the hSav1–
Mst1/Mst2–Nek2A pathway to enable centrosome disjunction
and spindle formation [6]. These interactions suggest a signiﬁ-
cant role of Nek2A in C-NAP1/rootelin disjuction, and are
considered as vital for centrosome disjunction. Furthermore,
Nek2A also has a binding site for the catalytic subunit of
PP1, and hyperactivation of Nek2A at the onset of mitosis is
thought to be dependent on inactivation of PP1 [26]. The
mechanism of Nek2A dynamics was proposed where the phos-
phorylation of HsSgo1 by Nek2A is shown to be essential for
faithful chromosome congression and the proper attachment
of the spindle microtubule to the kinetochore [27]. It has been
proposed that the Nek2A-mediated phosphorylation of
HsSgo1 links kinetochore-microtubule attachment to chromo-
some segregation dynamics [27]. Ser14 and Ser507 residues on
HsSgo1 are substrates of Nek2A in vitro [27]. Nek2 phosphor-
ylates the chromatin-associated protein, high mobility proteinA2, and is activated during the extracellular signal-regulated
kinase 1/p90Rsk2-stimulated condensation of chromatin in
mouse pachytene spermatocytes, suggesting its active role in
chromatin condensation [28,29]. All this evidence collectively
suggests that the Nek2A has a signiﬁcant role in regulating
the centrosome dynamics as well as in maintaining the spindle
checkpoint signals, thus becoming an important factor for reg-
ulating the cell cycle progression. Though the knockout or
depletion of Nek2A did not show any signiﬁcant effect on
G2/M progression the above observation makes it evident that
the alteration in its functional mechanism may alter the mitotic
progressions.
Nek2A has been shown to be actively involved in several
cancer cases [3–5]. It has been shown that the ectopic expres-
sion of kinase-inactive Nek2A interfered with proper bipolar
spindle formation and eventually resulted in chromosomal seg-
regation defects such as unaligned chromosomes in the meta-
phase, lagging chromosomes in the anaphase and thin
chromatin bridges in the telophase [14]. Furthermore, the
development of the Nek2-suppressed mouse embryos stopped
at the second mitotic division, whereas the development of the
Nek2-depleted Xenopus embryos stopped at the 16- or 32-cell
stage with irregularly sized blastomeres [30]. Its overexpression
induced premature centrosome splitting [9,31], whereas the
overexpression of kinase-dead Nek2A led to the formation
of centrosomal abnormalities, monopolar spindles, and aneu-
ploidy [14]. Nek2 mRNA was signiﬁcantly elevated in Ewing
tumour (paediatric osteosarcoma) cell lines and upon transfor-
mation of low-grade follicular lymphoma to the more aggres-
sive diffuse large B-cell lymphoma [32,33]. Nek2 was also
shown to display elevated levels of protein expression in hu-
man breast cancer [34]. There was a reduced amount in G1
and M phases compared with S and G2 phases. Growing line
of evidence has strongly suggested that the Nek2A may act as
a potential candidate for anti-tumour drug discovery.
4. Targeting Nek2A: inhibitor based approach
The structural conformation of proteins determines their
activity regulation mechanisms as well as their response to a
216 A. Kumar et al.particular drug inhibitor. Understanding the structural orien-
tations of the corresponding protein, and their respective prop-
erties, will help in determining the corresponding drug
response cascades and will eventually facilitate in the drug dis-
covery process. When we talk about drug discovery, the most
leading factor that governs the efﬁciency level of the drug mol-
ecule is the ﬁne-tuning of the molecular properties of drugs to
the corresponding structures of their protein targets, which
promotes the binding interactions of high afﬁnity and speciﬁc-
ity [35]. The protein-drug interaction events are governed by
the enthalpic and entropic contributions. The enthalpy calcula-
tions correspond to the stabilizing interactions, including
hydrogen bond and salt bridge formations whereas the entropy
corresponds to regulating the losses of conformational ﬂuctu-
ations occurring in the protein–drug complexes. These calcula-
tions together regulate the efﬁciency and the stability of drug
interactions with target proteins. Shape complementarity and
the physicochemical complementarity are the two governing
factors of enthalpy contributions in protein ligand interac-
tions. Shape complementarity permits the protein and small
molecules to achieve sufﬁcient proximity and contact surface
area to form stabilizing interactions, while physicochemical
complementarity determines the nature of these interactions
[35]. The most complementary conformation from an ensem-
ble of equilibrium structures is selected by the ligand mole-
cules. This mode of interaction has been implicated in the
binding selectivity of ligand to tyrosine kinases [36]. A recent
comparison of two protein structure datasets, one comprising
drug targets and the other of non-drug targets, revealed drug
targets to be more hydrophobic, have lower isoelectric values,
be composed of more amino acids and have a higher frequency
of beta-sheet secondary structure compared with other pro-
teins [37]. Inhibitor based targeting of Nek2A, thus requires
proper functional domain knowledge and the proper comple-
mentarity for ligand–protein interactions.
Nek2 is a serine/threonine kinase, dimerizes and is rapidly
activated by autophosphorylation. Besides autophosphoryla-
tion, Nek2 may be regulated by upstream kinases. Indeed,
the catalytic domain of Nek2 is phosphorylated in vitro by
p90Rsk2, an interesting observation as the activation of chro-
matin condensation by Nek2 in mouse spermatocytes is under
the control of the mitogen-activated protein kinase/p90Rsk2
pathway [29]. Recent studies suggest that RNAi depletion of
Nek2 leads to antiproliferative effects in HeLa, MDA-
MB-231, HuCCT1, and MCF7 cells in vitro and in vivo [23]
and cholangiocarcinoma cell lines [38]. The genetic knock-
down of Nek2 resulted in an antiproliferative and antimigrato-
ry phenotype in MDA-MB-231 breast cancer cells and an
antitumor effect in a MDA-MB-231 xenograft model when
the silencing oligonucleotides were injected intratumorally
[39]. It is found that the depletion of Nek2 synergized with
cisplatin in inhibiting the growth of colorectal cancer cells
in vitro and in vivo [40], although the mechanism for this
remains unclear. This provides a possibility to exploit the
structural composition of Nek2 protein for anti-tumour drug
development. Nek2 is composed of several pharmacologically
active domains which can be a good prospect for drug target
discovery. Amino acid region from 1 to 271 contains a highly
essential kinase domain with an activation loop segment from
159 to 186 [1]. Downstream of the kinase domain is an unusual
leucine zipper motif that mediates dimerization as a prerequi-
site for efﬁcient autophosphorylation and, thus, full Nek2activity on exogenous substrates [9]. APC/C targets different
proteins for degradation at different times in the cell cycle.
The Nek2A protein associates tightly with the APC/C, via its
C-terminal MR tail [41]. This interaction is considered as
essential for ubiquitylation and degradation of Nek2A in pro-
metaphase [41]. The KEN box of Nek2A consists of four phos-
phorylation sites, suggesting a potential autoregulatory role at
the level of Nek2 stability [1]. This region also acts as a recog-
nition site for APC/CCdc20-mediated degradation of Nek2A in
early mitotic stages [41]. The amino acid region between 399
and 445 is required for its proper neucleolar localization [1].
Two sites (Thr-170 or Ser-171, Thr-179) which map to the
Nek2 T-loop region, and a third, Ser-241, located within the
kinase C-lobe, indicate their potential role in regulating kinase
activity [1]. Moreover, the Ser-356 and Ser-428 residues lying
within the coiled-coil region are reported to be involved in
modulating Nek2A dimerization and localization [1]. The
DFG and HRD motifs of Nek2A are highly conserved and
contain catalytically vital aspartic acid residues. The activation
loop is immediately C-terminal to the DFG motif, contributes
to substrate binding and helps to organize other motifs, and
can be considered as the potential target for drug inhibitors.
Its C-helix contains a conserved glutamic acid that forms a salt
bridge with a conserved lysine residue. The hinge region of
Nek2A formed two hydrogen bonds with the aminopyrazine
ring of an active drug molecule [4].
The crystallographic study reported few unstable regions in
the Nek2A structure, forecasting multiple disordered regions
within the functional domains [1]. Residues within the loop
N-terminal to aC (Thr-45–Met-51), the loop connecting the
two strands b4 and b5 (Arg-77–Thr-81), the region C-terminal
to helix aE (Asp-132–Arg-140), and the activation segment res-
idues between Asn-167 and Val-177 were presumably found to
be disordered [1]. The N-terminal lobe (Ser-3–Met-86) and the
aC helix in particular have been shown to exhibit disordered
conformation, presumably due to mobility within the crystal
[1]. It shows that the regions are highly unstable and could
be possibly involved in rapid conformational changes for reg-
ulating the kinase activity of protein. Rellos et al. further
showed that the amino acid residues Met-86, Val-68, Phe-
148, Cys-89, and Leu-162 acted as active site residues forming
hydrophobic interactions with the inhibitor molecule [1]. Fur-
thermore, Glu-87 and Cys-89, which are the main chain resi-
dues, formed two hydrogen bonds with the inhibitor [1]. In
another study, Ile14, Gly91 and Gly92 also showed that a
promising result is obtained by proper positioning and hydro-
phobic interactions with the drug molecule [4]. The piperidine
rings of compound 2 and 5 and the phenyl ring of the benzoic
acid moiety of compound 12 were shown to be sandwiched be-
tween the gatekeeper residue Met86 and Phe148 [4]. Further-
more, the carboxylic acid group of compounds 2, 5, and 12
participated in a number of interactions, including hydrogen
bonds with Tyr70 and Asp159 and a salt bridge with the cata-
lytic Lys37 [4]. The Tyr70 residue is remarkable for two rea-
sons: ﬁrst, it is rare among kinases for Tyr to be present in
this position 23 and second, it shows an unusual conformation
in the structures with compound 2, 5, and 12. Presence of a Phe
(Phe148) at the base of the ATP pocket is also a notable
feature [4]. Only 39 of the human kinase catalytic domains
contain a Phe in this position which is usually occupied by
Leu in most kinases [4]. The larger Phe has a profound inﬂu-
ence on the shape of the ATP pocket [4]. It protrudes into
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the hinge binding motif [4]. The methoxy group of compound
15 formed contact with Val68 and Tyr70 [4]. In another study,
the aminopyridine group of rac-17j compound was observed to
form two hydrogen bonds with the hinge region at Glu87 and
Cys89 [42]. Moreover, the imidazole ring of rac-3 compound
formed one hydrogen bond with Cys89 residue. Met86 and
Phe148 form the gatekeeper component whereas the amide
group engages in two hydrogen bonds with the backbone
NH and the side chain carbonyl group of Asp159 of the
DFG motif [42]. The thiophene ring engages in hydrophobic
contacts with Ile14 and Gly92 [42]. This evidence collectively
reports the signiﬁcance of these functionally active amino acid
residues in the exploitation of target based drug design
approaches.
Nek2 dimerizes through a C-terminal coiled-coil domain
that is essential for efﬁcient cellular activity [17]. The auto-
phosphorylation of the Nek2A dimer is mediated by the
Thr175 residue [4]. There are different ranges of inhibitor mol-
ecules that can be exploited against the Nek2A activation. The
so-called ‘‘type II’’ inhibitors exploit an allosteric site present
only in the inactive ‘‘DFG-out’’ conformation, and their clin-
ical success has initiated efforts to develop new families of ki-
nase inhibitors that combine classical type I scaffolds with
chemical moieties that are known to stabilize DFG-out confor-
mations [1]. This particular conformation of the activation
loop is not accessible for every kinase and opens a binding
pocket with much larger sequence variability, making the
development of speciﬁc inhibitors more likely. Rellos et al.
have suggested two possibilities for the development of inhib-
itors that stabilize the inactive conformation [1]. They reported
that the type I pyrrole-indolinone scaffold in combination with
more bulky type II inhibitor moieties in place of the exocyclic
chlorine could be used to enlarge the allosteric binding pocket
[1]. Secondly, since aT helix prevents the access of Glu-55 to
the active site, they suggested that the surface presented by
aT helix could also be targeted to create more stabilizing inter-
actions [1]. Furthermore, it has been proposed that the auto-
phosphorylation of Thr-179, within the T loop, and Ser-241,
within the C lobe, may act to negatively regulate the Nek2A
activation. The C lobe Ser-241 residue regulates the dimeriza-
tion and thus plays an autophosphorylation mediated inhibi-
tory target. It has been shown that the C-terminal domains
are among the top 10 commonly observed folds that are used
as a target for the drug discovery process [35]. Stabilizing the
C-lobe with a type II inhibitor and then targeting it with a ki-
nase mimicking drug molecule may form an effective combina-
tion for inhibiting the dimerization and thus in negative
regulation of its functional mechanism. Molecular dynamics’
(MD) studies reveal that kinases with high ligand afﬁnity
spend more time in conformations compatible with drug bind-
ing compared with kinases with low ligand afﬁnity [35]. MD
simulation is a useful approach for generating protein struc-
tural ensembles and capturing alternative conformations that
may be relevant for protein function or small-molecule binding
[43,44]. Further, the application of MD simulations has shown
useful outcomes in studying conformational changes in protein
and its effect on its ligand binding afﬁnity [45–54]. Protein
dynamics information enhances structure-based binding site
prediction methods and reduces their dependence on experi-
mentally determined target protein structures [35]. Thus byMD analysis we can further examine the effectiveness of the
proposed inhibitor drug conformation.
5. Concluding remarks
Due to the recent advancements in genomic technology, the
area of therapeutic development has raised the possibility for
the treatment of several diseases [55,56]. Three dimensional
protein structure information is frequently used in drug devel-
opment practices, from the selection of a therapeutic target, to
the determination of underlying molecular mechanisms of ac-
tion, and their possible clinical outcomes on the target patient
population. As a result, great improvements have been made
in understanding the structure–activity relationship of inhibi-
tor-protein complexes and thus has facilitated in understanding
the core insights of drug–target interactions and in the develop-
ment of highly efﬁcient therapeutic agents. There has been a re-
cent case implicating the overexpression of centrosome
associated genes and their correlation with cancer associated
evidence, which has now attracted the genomics and pharmaco-
logical researchers in elucidating their underlying molecular
mechanisms of activity regulation and further in developing
effective inhibitor drug molecules. Nek2A is in special focus
since it has been observed in a wide range of breast cancer, ew-
ing tumour and in folicular lymphoma cases. Previously few re-
searches have been carried out on the development of effective
drug inhibitors to control the activity of Nek2A protein but
they have further argued on the requirement of further investi-
gation to derive more effective drugs. Release of several confor-
mations of Nek2A protein has now provided an easier way of
determining the potential target domains. Although the avail-
able protein structures may not display a conformation com-
patible with the inhibitor binding for the proposed
conformation, probably due to the protein structural prefer-
ences or sometimes due to the random chances and crystalliza-
tion artefacts, these errors can be resolved by incorporating the
MD simulation approaches. The collective information that we
presented in this manuscript strongly pinpoint to several amino
acid residues that lie in the out conformation attaining domains
and can be easily targeted by drug molecules. Further the pre-
vious reports also depict the use of kinase mimicking inhibitors
that can negatively regulate the activity of Nek2A by phosphor-
ylating few essential amino acid residues, such as the Ser-241
present in its C-lobe. This information will be furthermore
valuable to the in silico and wet lab researchers for developing
highly potent inhibitors against the Nek2A protein.Acknowledgment
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